

EC Certificate - Production Quality Assurance

Directive 93/42/EEC on Medical Devices, Annex V

No. CE 672663
Issued To: **Hunter Scientific Limited**
Unit 1, Priors Hall
Widdington
Saffron Walden
Essex
CB11 3SB
United Kingdom

In respect of:

Manufacture and final inspection of sterile Pasteur pipettes for In Vitro Fertilisation.

on the basis of our examination of the quality assurance system under the requirements of Council Directive 93/42/EEC, Annex V. The quality assurance system meets the requirements of the directive. For the placing on the market of class IIb and class III products an Annex III certificate is required.

For and on behalf of BSI, a Notified Body for the above Directive (Notified Body Number 2797):



Gary E Slack, Senior Vice President Medical Devices

First Issued: **2018-08-13**

Date: **2020-11-16**

Expiry Date: **2023-08-12**

...making excellence a habit.™

Page 1 of 2

Validity of this certificate is conditional on the quality system being maintained to the requirements of the Directive as demonstrated through the required surveillance activities of the Notified Body. This approval excludes all products designed and/or manufactured by a third party on behalf of the company named on this certificate, unless specifically agreed with BSI.

This certificate was issued electronically and is bound by the conditions of the contract.


EC Certificate - Production Quality Assurance

Supplementary Information to CE 672663

Issued To:

**Hunter Scientific Limited
Unit 1, Priors Hall
Widdington
Saffron Walden
Essex
CB11 3SB
United Kingdom**

Number	Device Name	Intended purpose per IFU
Class IIa		
MD 0109	Pasteur pipettes	---



First Issued: **2018-08-13**

Date: **2020-11-16**

Expiry Date: **2023-08-12**

...making excellence a habit.™

Page 2 of 2

Validity of this certificate is conditional on the quality system being maintained to the requirements of the Directive as demonstrated through the required surveillance activities of the Notified Body. This approval excludes all products designed and/or manufactured by a third party on behalf of the company named on this certificate, unless specifically agreed with BSI.

This certificate was issued electronically and is bound by the conditions of the contract.

Information and Contact: BSI, Say Building, John M. Keynesplein 9, 1066 EP Amsterdam, The Netherlands Tel: + 31 20 346 0780

BSI Group The Netherlands B.V. registered in The Netherlands under 33264284.

A member of BSI Group of Companies.

EC Certificate - Production Quality Assurance

Directive 93/42/EEC on Medical Devices, Annex V

List of Significant Subcontractors

Recognised as being involved in services relating to the product covered by:

Certificate No: **CE 672663**
Date: **2020-11-16**
Issued To: **Hunter Scientific Limited
Unit 1, Priors Hall
Widdington
Saffron Walden
Essex
CB11 3SB
United Kingdom**

Subcontractor:	Service(s) supplied
Advena Limited Tower Business Centre 2nd Floor, Tower Street Swatar BKR 4013 Malta	EU Representative
Riverside Medical Packaging Company Ltd Newmarket Drive Derby DE24 8SW United Kingdom	Packaging
Synergy Health Sterilisation UK Ltd (Synergy Health - AST - Thorne) 1 Alpha Court Capitol Park Thorne Doncaster DN8 5TZ United Kingdom	ETO Sterilization

...making excellence a habit.™

EC Certificate - Production Quality Assurance Certificate History

Certificate No: CE 672663
Date: 2020-11-16
Issued To: Hunter Scientific Limited
 Unit 1, Priors Hall
 Widdington
 Saffron Walden
 Essex
 CB11 3SB
 United Kingdom

Date	Reference Number	Action
13 August 2018	8727700	First Issue.
18 February 2019	8995683	Traceable to NB 0086.
Current	9719751	Addition of device schedule table. Addition of EU rep.

...making excellence a habit.™

Page 1 of 1

Validity of this certificate is conditional on the quality system being maintained to the requirements of the Directive as demonstrated through the required surveillance activities of the Notified Body. This approval excludes all products designed and/or manufactured by a third party on behalf of the company named on this certificate, unless specifically agreed with BSI.

This certificate was issued electronically and is bound by the conditions of the contract.

Information and Contact: BSI, Say Building, John M. Keynesplein 9, 1066 EP Amsterdam, The Netherlands Tel: + 31 20 346 0780

BSI Group The Netherlands B.V. registered in The Netherlands under 33264284.

A member of BSI Group of Companies.

Hunter Scientific Limited
Unit 1, Priors Hall
Widdington
Saffron Walden
Essex
CB11 3SB
United Kingdom

18 July 2023

Notified Body Confirmation Letter
Reference: EU2023-607/653680

To whom it may concern,

Confirmation of the status of a formal application, written agreement, and appropriate surveillance in the framework of Regulation (EU) 2023/607 amending Regulations (EU) 2017/745 and (EU) 2017/746 as regards the transitional provisions for certain medical devices and in vitro diagnostic medical devices

This letter confirms that, **BSI Group The Netherlands B.V.**, a Notified Body (NB) designated against Regulation (EU) 2017/745 (MDR) and identified by the number **2797** on NANDO, has received a formal application in accordance with Section 4.3, first subparagraph of Annex VII of MDR and has signed a written agreement in accordance with Section 4.3, second subparagraph of Annex VII of MDR with the following manufacturer:

Hunter Scientific Limited
Unit 1, Priors Hall
Widdington
Saffron Walden
Essex
CB11 3SB
United Kingdom

SRN Number (if available): GB-MF-000012822

The devices covered by the formal application and the written agreement mentioned above are identified in the Tables below. Table 1 identifies the devices for which an MDR application has been received, written agreement concluded and for which the NB is also responsible for appropriate surveillance of the

corresponding devices under the applicable Directive. Table 2 identifies the devices for which an MDR application has been received and a written agreement concluded, but the NB has not yet taken the responsibility for appropriate surveillance of the corresponding devices under the applicable Directive.

In the case of devices covered by certificates issued under Directive 90/385/EEC (AIMDD) or Directive 93/42/EEC (MDD) that expired after 26 May 2021 and before 20 March 2023, without having been withdrawn, this letter also confirms that the manufacturer signed the written agreement under MDR by the date of MDD/AIMDD certificate expiry; or provided evidence that a competent authority of a Member State had granted a derogation or exemption from the applicable conformity assessment procedure in accordance with Article 59(1) of MDR or Article 97(1) of the MDR respectively, by the 20 Mar 2023 for the relevant devices.

The transition timelines that apply to the devices covered by this letter, subject to the manufacturer's continued compliance to the other conditions specified in Article 120.3c of MDR (as amended by (EU) 2023/607), are shown below:

- 26 May 2026 for Class III custom-made implantable devices
- 31 December 2027 for Class III devices and Class IIb implantable devices excluding Well-established technologies (WET - sutures, staples, dental fillings, dental braces, tooth crowns, screws, wedges, plates, wires, pins, clips and connectors)
- 31 December 2028 for other Class IIb devices, Class IIa, Class I devices placed on the market in sterile condition or have a measuring function
- 31 December 2028 for devices not requiring the involvement of a notified body under MDD but requiring it under MDR (e.g., class I devices that qualify as re-usable surgical instruments)

On behalf of BSI Group The Netherlands B.V.,

Chuck Thomas on behalf of
Jaimie Jarboe
BSI Scheme Manager

Table 1: Devices covered by this letter and for which the NB is also responsible for appropriate surveillance of the corresponding devices under the applicable Directive:

Device name or Basic UDI-DI (under MDR application)	MDR Device classification (as proposed by the manufacturer and verified at the pre-application stage)	If the MDR device is a substitute device, identification of the corresponding MDD/AIMDD device	MDD/AIMDD Certificate Reference(s) of the devices under MDR application, and the NB Identification
5060168419019UC1	Class IIa	N/A	CE 672663

Table 2: Devices covered by this letter and for which the NB is NOT responsible for appropriate surveillance of the corresponding devices under the applicable Directive:

Device name or Basic UDI-DI (under MDR application)	MDR Device classification (as proposed by the manufacturer and verified at the pre-application stage)	If the MDR device is a substitute device, identification of the corresponding MDD/AIMDD device	MDD/AIMDD Certificate Reference(s) of the devices under MDR application, and the NB Identification
N/A	N/A	N/A	N/A

Confirmation Letter Revision History

Date	Action
2023/07/18	Initial issue

Manufacturer's Declaration

in relation to Regulation (EU) 2023/607 amending Regulations (EU) 2017/745 and (EU) 2017/746 as regards the transitional provisions for certain medical devices and in vitro diagnostic medical devices, in particular with respect to

- the validity of certificates issued under Council Directive 90/385/EEC on Active Implantable Medical Devices (AIMDD) or Council Directive 93/42/EEC on Medical Devices (MDD) (Directive Certificates) *and/or*¹
- the compliance of the devices and us as their manufacturer with the conditions for the continued placing on the market and putting into service

Manufacturer name	Hunter Scientific Ltd
Manufacturer address and contact details	Unit 1 Priors Hall Widdington Essex CB11 3SB UNITED KINGDOM
Single Registration Number (SRN) (if available)	GB-MF-000012822

Authorised Representative name (if applicable)	Advena Ltd
Authorised Representative address and contact details	Tower Business Centre, 2nd Flr., Tower Street, Swatar, BKR 4013 Malta.
Single Registration Number (SRN) (if available)	MT-AR-00000023

Notified body name (if applicable)	BSI <input checked="" type="checkbox"/> See attached schedule
Notified body number (if applicable)	2797 <input checked="" type="checkbox"/> See attached schedule

¹ The first condition is not applicable in case of devices for which the conformity assessment procedure pursuant to MDD did not require the involvement of a notified body, for which the declaration of conformity was drawn up prior to 26 May 2021 and for which the conformity assessment procedure pursuant to this Regulation requires the involvement of a notified body.



Directive Certificate number(s) to which this confirmation is made (if applicable)	CE 672663 ✓ See attached schedule
Original expiry date as indicated on the Directive Certificate prior to the extension of the validity (if applicable)	2023-08-12 ✓ See attached schedule
End date of extended validity/transition period	2028-12-31 ✓ See attached schedule

We, as the manufacturer declare under our sole responsibility:

- for the above listed **Directive Certificate** (or see attached schedule, if multiple certificates) the conditions for the legal extension of validity as required in Article 120.2 of the MDR are met *and/or*²
- the listed **device(s)** in the attached schedule and we as their manufacturer are in compliance with the conditions listed in Article 120.3c of the MDR for continued placing on the market and putting into service,

namely by fulfilling the following conditions:

➤ **Directive Certificate(s)** as listed above or in the attached schedule

- Directive Certificate(s) covering the listed device(s) was/were issued after 25 May 2017, was/were valid on 26 May 2021 and have not been withdrawn afterwards.

Choose applicable statements:

Expired *before* 20 March 2023:

- Before the original date of expiry as indicated on the Directive Certificate(s), we and the notified body have signed written agreement(s) in accordance with Section 4.3, second subparagraph of Annex VII to this Regulation for the conformity assessment(s) in respect of the device(s) covered by the expired certificate(s) or in respect of a device(s) intended to substitute that/those device(s), or
- A Competent Authority has granted a derogation from the applicable conformity assessment procedure in accordance with Article 59(1) MDR (may be provided upon request), or
- A Competent Authority has required the manufacturer, in accordance with Article 97(1) MDR, to carry out the applicable conformity assessment procedure (may be provided upon request)

Choose one of the following statements only if a derogation per Article 59(1) or a requirement per Article 97(1) has been granted by a Competent Authority:

- Formal application(s) to the notified body in accordance with Section 4.3, first subparagraph of Annex VII MDR for conformity assessment has/have been made or will be made/submitted by us to a notified body no later than 26 May 2024 for the device(s) listed in the attached schedule or its/their substitute(s) and signed written agreement(s) is/will be

² The first condition is not applicable in case of devices for which the conformity assessment procedure pursuant to MDD did not require the involvement of a notified body, for which the declaration of conformity was drawn up prior to 26 May 2021 and for which the conformity assessment procedure pursuant to this Regulation requires the involvement of a notified body



in place in accordance with Section 4.3, second subparagraph of Annex VII MDR before 26 September 2024.

- We do not intent to lodge an application for conformity assessment by 26 May 2024, therefore the transition period will end on 26 May 2024.

- Expired/expires *after* 20 March 2023:

Choose one applicable statement:

- Formal application(s) to the notified body in accordance with Section 4.3, first subparagraph of Annex VII MDR for conformity assessment has/have been made or will be made/submitted by us to a notified body no later than 26 May 2024 for the device(s) listed in the attached schedule or its/their substitute(s) and signed written agreement(s) is/will be in place in accordance with Section 4.3, second subparagraph of Annex VII MDR before 26 September 2024.
- We do not intent to lodge an application for conformity assessment by 26 May 2024, therefore the transition period will end on 26 May 2024.

➤ **Upclassified devices**

In case of devices for which the conformity assessment procedure pursuant to MDD did not require the involvement of a notified body, for which the declaration of conformity was drawn up prior to 26 May 2021 and for which the conformity assessment procedure pursuant to this Regulation requires the involvement of a notified body:

Choose one applicable statement:

- Formal application(s) to the notified body in accordance with Section 4.3, first subparagraph of Annex VII MDR for conformity assessment has/have been made or will be made/submitted by us to a notified body no later than 26 May 2024 for the device(s) listed in the attached schedule or its/their substitutes and signed written agreement(s) is/will be in place in accordance with Section 4.3, second subparagraph of Annex VII MDR before 26 September 2024.
- We do not intent to lodge an application for conformity assessment by 26 May 2024, therefore the transition period will end on 26 May 2024.

➤ **Quality Management System (QMS)**

Choose one applicable statement:

- A QMS in accordance with Article 10(9) MDR will be put in place by no later than 26 May 2024.
- A QMS in accordance with Article 10(9) MDR is in place.
- A notified body has issued the attached certificate for the MDR-compliant QMS.

➤ **Device(s) as listed in the attached schedule**

- The device(s) continue to comply with the AIMDD or MDD.
- There are no significant changes in the design and intended purpose.
- The device(s) do not present an unacceptable risk to health or safety of patients, users or other persons, or to other aspects of the protection of public health.

Signed for and on behalf of the manufacturer:

Full Company Name:

Hunter Scientific Ltd

Location & Date:

Unit 1 Priors Hall

Widdington

Essex

CB11 3SB 1st August 2023

Signature:



01 Aug 2023

Print Name:

Allen Goddard

Title:

Regulatory & Compliance Manager

Contact Details (at least email):

allen@hunterscientific.com

Schedule of Devices

The above Manufacturer's Declaration is valid for the following devices:

Identification of the device(s) ³ (e.g., device name, family/group name device model or catalogue number)	Directive Certificate number(s) to which this confirmation is made (if applicable)	Original expiry date as indicated on the Directive Certificate (s) prior to the extension of the validity (if applicable)	Notified Body name and number that issued the Directive Certificate (if applicable)	Notified Body name and number where the MDR application was lodged/contract signed (if applicable)	End date of extended validity / transition period	Substitute Device(s) (if applicable)
Hunter Sterile Pasteur Pipette	CE 672663	2023-08-12	BSI 2797	BSI 2797	2028-12-31	N/A

³ for devices with AIMDD/MDD certificate(s) the identification should be as in the certificate, and only if the certificate has a generic scope it should be as defined above)